Startseite Comparison of two immunoassays for determining hepatitis B virus serum markers
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Comparison of two immunoassays for determining hepatitis B virus serum markers

  • Wanzhou Xu , Yan Li EMAIL logo , Ming Wang und Jian Gu
Veröffentlicht/Copyright: 28. September 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: To evaluate and compare the detection efficacy of serum hepatitis B virus (HBV) markers by two immunoassays: electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA).

Methods: ECLIA and ELISA were used to analyze 359 serum samples, including 64 HBsAg/anti-HBs coexistence serological pattern samples (samples positive for both HBsAg and anti-HBs), 24 HBeAg/anti-HBe coexistence serological pattern samples (samples positive for both HBeAg and anti-HBe), and 271 normal serological pattern samples (negative for either of the combinations).

Results: In the normal serological pattern samples, the concordance rates of the two methods in detecting serum HBV markers were as follows: 97.05% for HBsAg, 92.62% for anti-HBs, 100% for HBeAg, 76.75% for anti-HBe, and 58.67% for anti-HBc. The differences in the qualitative criteria for anti-HBc and anti-HBe were primarily responsible for the discrepancy between the two methods (κ-values of 0.657 and 0.253, respectively). Most weak positive results, determined by ECLIA, were negative determined by ELISA, whereas the results of HBsAg, anti-HBs, and HBeAg detection were generally consistent. In the HBsAg/anti-HBs coexistence serological pattern samples, the concordance rates of HBsAg and anti-HBs detection were 98.44% and 34.38%, respectively. The positive rate of ELISA does not vary as the COI (cut-off index) varies which was determined by ECLIA; in the HBeAg/anti-HBe coexistence serological pattern samples, the concordance rates of HBeAg and anti-HBe detection were 45.83% and 79.17%, respectively. Most weak positive results, determined by ECLIA, were negative when determined by ELISA.

Conclusion: The discrepancies between the two assays in normal serological patterns samples and HBeAg/anti-HBe coexistence serological pattern samples were mostly due to the different sensitivity of the two assays, but for the HBsAg/anti-HBs coexistence serological pattern samples, the discrepancy was not caused by the different sensitivity. It is the difference in determining anti-HBs which led to the discrepancy.


Corresponding author: Yan Li, Department of Clinical Laboratory, Renmim Hospital of Wuhan University, 99 Ziyang Road, Wuchang, Wuhan, Hubei Province 430060, P.R. China Phone: +86-27-880 71553, Fax: +86-27-880 71553

Received: 2011-7-3
Accepted: 2011-8-28
Published Online: 2011-09-28
Published in Print: 2012-01-01

©2011 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Editorial
  2. Targeted therapy for HER-2: personalized medicine for her, too
  3. Review
  4. Circulating levels of HER-2/neu oncoprotein in breast cancer
  5. Mini Review
  6. The human epidermal growth factor receptor 2 (HER2)
  7. Opinion Paper
  8. Proposed criteria for sorting examined properties in clinical laboratory reports
  9. Guidelines and Recommendations
  10. Properties and units in the clinical laboratory sciences, Part XXIII. The NPU terminology, principles and implementation –a user’s guide (Technical Report 2011) (IFCC–IUPAC)
  11. Genetics and Molecular Diagnostics
  12. Establishing high resolution melting analysis: method validation and evaluation for c-RET proto-oncogene mutation screening
  13. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples
  14. General Clinical Chemistry and Laboratory Medicine
  15. A risk-analysis approach to the evaluation of analytical quality
  16. C-statistics versus logistic regression for assessing the performance of qualitative diagnostic tests
  17. Detection and quantification of M-proteinemia: comparison of various methods for serum protein electrophoresis
  18. External quality assessment of point-of-care International Normalized Ratio (INR) testing in Europe
  19. Comparison of two point-of-care testing (POCT) devices for fetal lactate during labor
  20. Simultaneous quantification of 19 drugs/metabolites in urine important for pain management by liquid chromatography-tandem mass spectrometry
  21. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal
  22. The old and new tests for celiac disease: which is the best test combination to diagnose celiac disease in pediatric patients?
  23. Improving diagnosis of adult-type hypolactasia in patients with abdominal complaints
  24. Synovial and serum levels of uncarboxylated matrix Gla-protein (ucMGP) in patients with arthritis
  25. The diagnostic performance of allergen-molecules in comparison to allergen-extracts
  26. Analytical performances of cystatin C turbidimetric assay: which impact on accuracy of glomerular filtration rate estimation in renal transplantation?
  27. Evaluation of Aution Max AX-4030 and 9UB Uriflet, 10PA Aution Sticks urine dipsticks in the automated urine test strip analysis
  28. Reference Values and Biological Variations
  29. Diurnal variability of total calcium during normal sleep and after an acute shift of sleep
  30. Infections Diseases
  31. Comparison of two immunoassays for determining hepatitis B virus serum markers
  32. Cardiovascular Diseases
  33. Ultra-sensitive troponin I levels to exclude acute myocardial infarction from myocardial injury
  34. Diabetes
  35. Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy
  36. Letters to the Editor
  37. Serum HER-2/ECD analysis in monitoring breast cancer patients
  38. No evidence for the involvement of the lipoxin A4 receptor (FPR2/ALX) gene in the susceptibility to coronary artery disease
  39. Does the presence of 3-epi-25OHD3 affect the routine measurement of vitamin D using liquid chromatography tandem mass spectrometry?
  40. Validity of the measurement of capillary cholesterol in the diagnosis of defined hypercholesterolemia
  41. Prelims
  42. Prelims
Heruntergeladen am 20.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm.2011.721/html
Button zum nach oben scrollen